• Aucun résultat trouvé

en fr

N/A
N/A
Protected

Academic year: 2021

Partager "en fr "

Copied!
189
0
0

Texte intégral

(1)

HAL Id: tel-01446754

https://tel.archives-ouvertes.fr/tel-01446754

Submitted on 26 Jan 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of sci-entific research documents, whether they are pub-lished or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Déterminants du risque hémorragique et thrombotique

des anticoagulants oraux et études de bon usage

Johana Bene

To cite this version:

Johana Bene. Déterminants du risque hémorragique et thrombotique des anticoagulants oraux et études de bon usage. Médecine humaine et pathologie. Université du Droit et de la Santé - Lille II, 2016. Français. �NNT : 2016LIL2S012�. �tel-01446754�

(2)

UNIVERSITE DE LILLE II

Faculté de médecine

Année 2016 N° __________

THESE

POUR L’OBTENTION DU GRADE DE

D

OCTEUR

de l’U

NIVERSITE

de L

ILLE

II

Discipline : Pharmacologie

Présentée par

Johana Béné

_________________________

Déterminants du risque hémorragique et thrombotique

des anticoagulants oraux et études de bon usage.

_________________________

Directeur de Thèse : Sophie Gautier Soutenue le 21 septembre 2016

JURY

Maryse Lapeyre Mestre Président

Céline Verstuyft Rapporteur

Antoine Pariente Rapporteur

Sophie Susen Examinateur

Vincent Berezowski Examinateur

(3)

!""#"$% & % ' ( ) & ' * + , - - . / ) + 0 1 ) ' + + 2 % - 0 3 & +) , 0 ) 4 * 5 0 6 7 - -8 . )

(4)

% - 9 2 4 .% :; 7 / ))$) < % =>>? 2# /42 * ) , 3 % - @ / A .) - % 5 .% =% % % 3 % % -,B!C - & % % B% / 4 -, % 3 % 2 4% ) 9 D . 3 ; % 3 / $ / % % . 3 / ) 5 % - -8 / 4 ) % / / 3 A / - 3 : % & 0 / - 4 ))) 8 . 4 E 8 % 2 : & -- / 8 4 F ) % / / E - / = G3 C / - 4 - 4) & ) , *% ' % & 7 % & H % % % ) 5 : - / 4 I ) , 3 % C H : 3 % / 3 ) & % % ) ' = / % :

(5)

, 3 % % D + ) 4 / ) & ) & / 0 % 4) 3 ) , % % % 1 % 4 - & C & - 2 C

(6)

Introduction ... 1

Les antivitamines K, pionniers dans l’anticoagulation par voie

orale ... 4

! " #

Les anticoagulants oraux directs, révolution de l’anticoagulation

orale ... 14

" $ $% " & ! " " $ $% " &# ! " ! # $ % ! $ ! & $ '$ " $ $% " ()

Iatrogénie liée aux anticoagulants oraux ... 26

'$ ! '$ (#

'$ ! '$ )(

$ ** )+

Critères de choix des anticoagulants oraux ... 38

** " " "$ ),

(7)

' (" ) " " * & ' (" ) " " *+, &-/ " +( 0 $ '$ $ +( 0 +) 0 ! " 1 " + 0 $ +# 0 $ " $ $% +2

Présentation du travail ... 61

Travaux de recherche ... 63

$ * " $ '$ / ! '$ ! '$ 3 / " $ $% #) (" . $ % / % * 0. " % $* % 1* 0 * $ " ! 2 "" 3 #-$ $ " $ $% " 4( " " " ! 4 % % 5 "$ 6% " -4 % % 5 "$ ((

Article n°1 ... 142

Article n°2 ... 159

Article n°3 ... 168

Article n°4 ... 179

(8)

Discussion ... 198

Conclusion ... 205

Références bibliographiques ... 206

Annexes ... 227

% & ((2 % ( ((, % ) ()5

(9)

6 78

* $

!!! !"# "$ % & '! ( %)* +,( ! -,. /(, 0 & 1 # * & 2 3 & 4 3 ,5. 6 7 ,5. & 66

8 & & & 3 3,5. "!"

8 & & & 39 & "!"

8 & & & 3 "!

, ,5. "!4

, ,5. & && ,( & "!$

Figure 15. Inconvénients des AOD par rapport aux AVK pour les médecins généralistes. "!'

: & & ,5. "!

* & & & & +,5. ; -<= ""4

* & & & & +,5 . ; = "#!

(10)

89

$%

. / & , "" : & ,5. 2 7 $ & ,( ,)( 4! & 1 1 4 > & ,( 4 ? $' >* , >* $

: & & & +,( '6

( %)* +,( ! -,. /(, 0 & 1 # : & & 1 & 1 $ @ + 9 3 ,( A,%8

* & 2 & &

+

* & 2 3 & #

& & & & ,( !" !"' 6

& & & !"' 3 6

. & + 6'

B 2 ,5. & 6

& & + ""#

(11)

89

> + & ""6

& & & " "

% " #

& & 3 "#

. & & & "##

> & "#$

(12)

0 :; * 7 2 * 7 * 2 * " *89 2 * 8 " 9 *+, 2 * " + ! , * 40 2 * 5 4 0 % *9,40 2 * , "" *9 : 2 * " 9 " : * 0 2 * " 0 " * 2 * 00 2 0 0 %" ! 0; 2 0 5 < ; 0;< 2 0 ; % " < 0"0 2 0" " 0 08* 179 2 0 8 " "=* " 7 "" 9 " 0: 2 0 : " " 0> 2 0/ ,,? 2 , , ( ? " @ 4AB 2 4 "" A " B ( 4 * 2 * 4 % 4 2 4 " " 49 2 4 " 9/ '* 2 ' "" * " '*8 2 ' "" * " 8 " "

(13)

0 :; ',* 2 ' , * ;*9 2 ; * 9 ; 0 2 ; 0 C , 2 ( / 8: 2 " 8 " D : 94 2 " 9 4! 74 2 " 7 4 " 8*0+ 2 8 ! * 0 " + ! 8 ;99 2 8 " ( ; " 9 E 9 4 2 $4 %" 1 % 2 "/ % 1 A: 2 " A : 9 2 " 9/ @ $ ( 7A 2 @ 7 " A 7; 2 @ 7 " ; F* > 2 F " /1* G ( > 90* 2 9/ 0 * 9 : 2 9 " : 98 :* 2 9/ @ 8 " $ ( : "$* " 70* 2 7 % 0 % " * 7F 2 7 % F E 7 2 7 ( <A, 2 <" @ A , " +:0 2 % ! : 0 %" !

(14)

; : 8< :;

$"

%" ! . " H* I " " " $ " ! % " " J ( . " (" . % ( ( ) . " % % "$ " " % " % " " . " ( % $ %" 5 . %" % " $ " " $ " " % % " % $ * 1 "5 " "" . . % $ . 5 "$ $ " % "@ $ % " $ 1% % " " % % " 5 H . I $ - " "$ " % " "$ $ "" " %" % % %% ! * 0 "" " " . %% " " % @ K 8 ! * " + ! L K 8*0+ L %% " K * " + ! , L HK *+, LI "" % " ' 2 " ! " H ! M. B " I. " ! HN " M. B / I "$ % ! H4" M. B "1 / 9 I " " " " % % /" ! % % @ % % @ " H 7;. 7AI ( $ " . " " * . % " % @ $ "" ( $

(15)

; : 8< :; " H* I " % " / H49I " ! H* 0I D " % / ( "" " " " H'*8 I % % " . "$ % " " ( . % % " " "$ " . " % *+, % $ % * *+, (( % " " ! % ( " % % / % " . 5 " % H " % % " " % " ( G " " I 0 % " % "$ %% "$ (( (( " 9 "$ " " "" " % " H " I % . ( " % % ( " . " % " . . % " " *+, % % "$ %" % $ % G "$ *+, " '* % K ! " L. K " 8*0+ 2 " O L. K " ( " " * L. K < " = ! P % L K , '" "$ % % L H Q#I $ " . R " . ( 5 "" % " ( " < " ! " " "" % "" % % % % .

(16)

; : 8< :; " % ! % 5 " " " ( S 0 " $ . % @ " " " * . " *+,. " @ 5 " % . " ( 5 % % % " % % . 5 % " ! "" " " " !. % " " ( 5 " $ @ " " "

(17)

; 0 ; &

=

/

"

$

* @ " " % 4 ' . . "" % % * . % %" T " % % " ( ) H-. I " $ % $ % . U $* / % " % #. "" 5 .- "" G 5 .& "" H I 8 . " " @ "$*89 $ " &. ' . % $ " * % . T 5 .#T ( " . 5 "$ *+, " "$ ( "" " H'*I H I $* . %" " " !. "$C 2 ' . 3. T $* . .3T . #.-T # # . #.3T %" - H I * ". 3. 5 T " % % " % " % % $* H % " " V ( I. % * " .3 "" ! 4 1< H I $ " * " " 2 " " % " : "$* " F

(18)

; 0 ; 3 * " '* % T 5 T H I % % " 5 " "" " % % " "$ "$ " " . % " "" " 4 ' . $ " (" % " G * 4 . "" - T % % $* H I V ( "$ " % " P . % " "$ " "$ " H . T # . &T I % ""@" " V ( H . T # . &T I H I 9 " " "$4 "" A " B ( H4ABI. "" S #@ ( " "$* " " ". " " " " % . "" % ( " ! % " ! % " 5 %" # G . " "/ (( " % G H-I 2 - " G #3 %" " %" !% ! * H% @ T $ ! % * I W - "$C / " $* # .3 W - 3 .#T W

(19)

; 0 ; - " (" . % - .&T ( . " " " " %" " W - " % %" 6 " W - " % " " "" ! " 4 3. " , 0 " ; E , % " % " " . " ". " % " " . H &I 0 " " % ! 8 " / " "" "$* 4 , / " " / % % " 7 % / % H 1 /"1 .&1 % I % % U % /"/" H% /"" I. % % /" H I. % / @ H I H( I / % " " (" " H @ I " %% % "$ " H ! @ I %% G " % . X SE SG H 3I (( " 5 " . " % ! P

(20)

; 0 ;

#

( " " / " @ (( 0 %% " "

% " "

Figure 1. Structure chimique des différentes formes de vitamine K.(14)

% % " % " " 5 " / @ % . . " " " " 9 ( . " ( % " Y1 !/" . " % " " % 0 Y1 !/" 2 - ( % 1 " 2 ( H% I. H% I. N H( 1 % " BI. N H( 9 I W - ( " 2 % 0 % 9 H " I

(21)

; 0 ;

-Tableau 1. Demi-vie des facteurs de la coagulation vitamine K dépendants.

6 " $ " $ 1 >! $ ? 6 " $ " $ . . N. ' 1 % " B & N. ' 9 & 6 " $ " $ 0 9 " !/" /% Z:101H0++;I [ ( ! 0 \ " ( " . % " = " % % " % "" " 0 !/" = (( % = !/ @ . !/ H ; I H( I !/ !/" % % !/ 1 8*, ;1 1 . %% " % . 5 " % " ( % "

Figure 2. Cycle de la vitamine K. (14)

; 2

(22)

; 0 ; " * "$ % !/ %P " " H( I ( " " % " / % " ( ( . K 1Y1 !/" L. %% " * H: % 1 , ( , I * . % " " ". ! 4 1< " " & H &I F " %" 6 . " . ( $*" 0 $ " " ". U 9 ( " . " " " " 5 "$ ( @(" ! " " " " " " H"$ $ %% "" $ "" " "$ " " I "" 1 % ! 4 . " " " " . &1 / !/1 . . $1 /" . % ! " % " E "$ J H I F " %" . &3. " E $ 5 "$ ( " " " 4 &-. " / " V ( H / ( 5 % K C , * L (( ! I. " " $ % D (( " 4 &-. " V ( " " ( " D "$; $ % 0 % . " % % $ % 5 " %% "

(23)

; 0 ; "$ ". " % @ @ " V ( D "$; 0 " %" (( " ". "" 1 ( " 3& $ " V ( ( % " $ #&. " 9 (" " Y1 !/" ( " " % H #I * G ' . ! ( "" $* " 2 2 " " % " (" H M I W 2 " V ( H0 M 3 I "$ " H M 9 M & I ! " " '$ * " % . % % " ( ! ! % %" % H] 3TI "$ " ( % % " % @ " % % " . ! !%" " * (( " % % % " / H0> I &3 0 H G I " 0> * . 0-. 0 -. 0 . *& H I % P ( " ( H -I 0 % " " %

(24)

; 0 ; % " (" 0 @ % . " % " " " . $ "" ( P " H Q I 0 " %" 2 $ % $ H %" " I " $ (( % " % "/ % @ / H Q &I 1 $ " " " " 2 " "$ ". " " V ( " (" H " I 4 . " (" 5 "$ " %" ( " " " 1 %" " . " !% 5 % "$ " % ( "" $* 5 1 " H 3I $ " * % " " G % @ "$ P " "

Tableau 2. Anti vitamines K commercialisés en France.

" 1 >! $ ? $ / " >@ $ ? . > -@? " > ? " < ; " "

* " 9 M -1 1& 1 & &

M 31 1& 1 8 " '" M & J ( 0 M 31&3 &13 1 3 3 0 M 31&3 &13 1 3 *% @ " . " * " % " " * & " * /% % " 5 # % @ " % @ % " $ % $ " ( " G5

(25)

; 0 ; / % ( "$ ! " 1 " %" H( . I. " ! " 1 " %" " H( I * . "$ " $ % * %" G $ '$ " % " $ " "$ (( * % % P (( " 2 "$ 8: " 8 " D : 0 $ !% % F E H7FI % " " H % % " ( 9 I (. " %" . " % " " H 8: ^ H7F % S 7F I9I 7F !%" ( % H( . . NI 0 $ !% " " " % "" "" " ! % 4 % * . "$ 8: $ G " ( " 5 . , " G . 8: " " .3 < 8: ( 5 ("@ " (( " $ 8: % 5 ! @ $ " , . " % ( "" " " / % @ " " 5 @ @ / " . "$ 8: " %" " H &.3IH I * . " ( 8: 6" ( $ " " " " % % !

(26)

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

(27)

; <: 78 ; : 89 < &

"

$

$%

" =

$

/

"

$

, % . % @ " ! * . % " ! "" " $ " 2 2 " " . " " % K 1 L. " "" % % " ! " H ! MI W 2 " ( N . " " % K 1! L. % "" % " ! HN " MI. "$ % ! H4" MI "$ ! " $ $% " 0 % . ' . " " ! $ $ ! @ H( I 4 . ( " 08* 179 H0 8 " "=* " 7 "" 9 " I % ) $ " !. . T " % % " % " " * % . " *+, " @ % " (( # "" ( G " @ H,,?I "" . ` 5 "$ " " * "$ " " % " $ " *+, % . T 5 . T

(28)

; <: 78 ; : 89 <

3

Figure 3. Evolution de la consommation des anticoagulants oraux en France entre 2000 et 2013. (10)

* *+,. 5 % "$4AB. " ! $ " ! " G $ H . T % " . T % " ! I % "$ " ! % "" " H . &T . TI H I $ " $ " " . 5 . T " "" ! G $ % " . #T $ % ! 5 "5 @ ( " . " 1 $ / " "$ '* ( H I "" % %" " . G . % "$ " ( " 08* 179. " % % /% $ " " " 2 (" H . TI.

! H . TI. V ( H .-TI. H . TI. " H . TI

% ! H . TI H I % % " " ! % " "

"$ " " % % * % %" C

! % *+, H%a . I % % G - %"

(29)

; <: 78 ; : 89 < ! " " $ $% " % ! " H ! MI. " " " . " % " " B " . " ( ) - " % @ " ! D " % / ( $ % % 7A 7; H " " 5 #3 5 I 4 ` . " ) * " % * 0 49 D " % % '*8 5 %" ( H " " 5 3 I " " ! M 5 3 % " G "" " ( " $ " " % % ( H7 I " % " H4 I. ! 3 *% @ " . " ! " % %"@ " " ( " %" " % 1 . ! " . % % (. % / "/ "/ % . " % % " " H " I % " " $ .3T % @ " *% @ " D " . " % ( " % % % " %" . ! " .3 5 % @ " % ( " " ! % %" H &1 3TI " % " 5 # "

(30)

; <: 78 ; : 89 < # 1 " / & 5 # D " " H I 0 1 % " ! " " 9 " ( % % " % ( H-3TI 9 1 % " $ " " ( " $ " % .# ( %" " D " " (( " H " " . 0"0 a 3 S S .# bI @ H0"0 a S S .# bI. 1 ! ( %" " . D " " ! " 1 $ (( " @ ! " % "" % $ ((" ! "/ % 1 H 1 %I. " $ % $ (" % " $ % " % " 0> &3 = ! (( " D/ 0> &3 , " 5 / @ % " % ! HN " MI. " % " " B / M. ( N . . % ( 5 . " % @ " ! D " % " ( $ " % " H 7; 7AI * ! 3 . " N " M % " . " % * 0 49 D " % '*8 "

(31)

; <: 78 ; : 89 < -7 " % @ " ( 7 $4 5 7 c D "$ " 4 . " ' , * H',*I. ! 4 1 < . ( " $ ! $ " " % H ( / H , I. @ " . * 0I % @ / H90*I D " " 5 H " I 5 %" 0 " " "$ *7 *9 *09. ! " = % %%" %% % " " % = % (( 5 " !% " ',* H I * " % " . " 0 5 H0; I "=* 4 % H4 *I 5 " ( " 5 "= ! = ! H I ! ( % G % $ * R " % % 5 " % " .3 ! SG % " " ! " H- 5 TI H " I " % ! " 5 & % @ " % % *% @ % " ! . 1 " / # 5 ! ( " ! % %" H 5 3TI % " 5 "$ " " 3 " 9 "$ " " ! . " S %

(32)

; <: 78 ; : 89 < " H " ( I. " " % " "$ % ( " " ! " " ( . "" % " * % % " $ D " % $ (( " " @ H0"0 2 3 5 - S S .# bI H0"0 2 5 & S S .# bI 4 $ (( " @ H0"0 2 3 5 S S .# bI " ! P " % 4 ( . 0"0 a 3 S S .# b. " ! $ % " ! $ (( " 0> &3 *&. ? $ % / % " % $ ((" ! 1 % ! ( % " % % " % " %" . " G ( $ % " " % " ! % " % "" (( " 5 " % / % < ( N . "$ % ! . " % " " B "1 / 9 . % @ * % % " % " " " % @ % .3 " ( " "$ " '* % !

(33)

; <: 78 ; : 89 < .3 3 " " % @ " ( 7 $4 D "$ " ! .3 3 % " " "= % ! = 3 T % "" G =5 H " I * d 3 . "= % ! % " " % " = % ! % " ! " H0 !I 5 & % @ " % % " ! % %" "$ % ! = -# T " = " = " "= % ! 2 3 T " D "= ( " . " G " " "" = " " "= % ! % % # T " " . " " % " " " 1 $ " "$ % ! = = % ! " % " 0> *&S3 H G I " 0> * . 0-. 0 . 0 ? H I % % % " " % "= % ! . " ( " = % ! " % % 1 % " % HB0: I 0 D " = (( " " @ H0"0 2 3 5 -S S .# bI. H0"0 2 5 & S S .# bI @ H0"0 2 3 5 S S .# bI. " %" "= % ! % . && T. % %% ! / " "

(34)

; <: 78 ; : 89 < " 4 $ (( " @ " % " "$ % ! P / % & $ ! . ( N . "$ " ( "" *+, " %% % " " , 9 E/ * "" " ' . " % " ? % . 4 . : / 1< . *"" . 9 ! / B " % " ! M H . &I $ ! " % * 0 49 D " % '* 5 " % % G . " " % 7 4 " "$ % G 5 " % " " % % G H 3I $ ! . %" ! " 5 H " I 9 % " " $ T " / # " . " " ! % %" $ 33 T 5 "$ $ " G ( % " %" "$ ! ( " % " % / "/ H% " !/" I. G !/ % " 0> *&S3 5 T " % @ " ( " % % " % T "$ !% 5 " " " @ "$ !% ! " ( 5 3 T $ ! " 1 % 0 D " " . " " " He I " S W " " " % 3 T " " " H " S I 4 3

(35)

; <: 78 ; : 89 < T " " % " . " " "$ ! " S " $ " 4 ( " 1 "$ % ! % 5 & < % % " H % G " % I $ (( " @ . % ( 5 E . % " 1 % " " % . " . "$ / / " E D " . "" "$ : < " '$ H Q& I % % % ! " . " ( " ( N #3 3 .3 3 .3 3 $ - $ , "! / 1 ( SG 1 ( SG ( SG ( SG T T 5 3 T T ** 8 \ T 8 \ 1 T " '$ 1 1& 1& 1 A / 1 # 31 -1 3 1 $% '$ 3T ] T -#T & 13 T - T T 3T 31 T 0 '$ * 2 4" 2 1 % 0> *& 1 % 1 % 2 "/ % . 0> 2 / &3

(36)

; <: 78 ; : 89 < $ '$ " $ $% " 4 % . " *+, % " " $ 2 " 7F "" ( ) " " %" " ! @ ( " "$ % ! "$ H& Q&3I D % "$ 8: $ %%" % ! *+, % % " H70*I % " ( ) ! 0 ! "" ! . % % "$ % ! ( H& I " "$ "" 70* " "$*+, " (( %" % " " %" ( * ". " 7F " 70* % % 5 " "" " *+, $ % "$*+, " ( " % " @ % % . % "$ $P %" . % " ! " " " ( " 5 " . @ " . ( ( " " % P " % " % % *+, H& I % % P " " ( "$ " A C 5 " . % " % $ ! " " % H&#I 0 $ % " ! 1N $ 1N % " % ! % " < N S " " @ " 1 "5 " "

(37)

; <: 78 ; : 89 < & % % $ " H&#I 4 % . H G ( % 5 I. " %" $ 1 1N % " % ! *+,. 5 "$ " " !% % " S H " &I 0 " %" . % " $ % " ( ( " " " . " % % G H% " I. "$ " @ % " ( " % . " % " ( " 0 E ( A " * . "$; " M 7 . B % M , 7 H ;/% B I 40*17M D , 9 M " %% " % % " % 1 51 " $ " $ % " " %" " " % %" " 0 " % " " " $ "/ " " "$ 1N " " H97*M 1 1N . , 9 W B % M , ' N . ;/% B . ; 1N M /. 7 1N M 7 " I H&-I 0 % % % " " " " A ; HA % $ P ; % I % % . $ % % . "

(38)

; <: 78 ; : 89 <

3

" " " 7F 70* % " " !

H& I < 7F " 5 70* " % " "

! @ ( " Ha S I

Tableau 4.Concentrations plasmatiques des AOD administrés aux doses maximales journalières.

H& .& .3 I

< % > - ? < > - ?

(1 ! $ &( ! $ ( ! $

, H 3 ! SGI #3 H #1 #3I H 1 & I

: ! H SGI H 13 3I H 1 I *% ! H3 ! SGI # H3#1 I 0 ! 2 ! " . 0 2 "" ( % " " %" $ *+, % H % % " % ( %" 5 " % I % " 0 % " " D ( " H3 I

(39)

:7 ; ; <: 78 ; : 89

$%

"

$

$%

7 " (( " $ " " ! " 5 % % . % " % "" 0$ $ "" " % " " % " " *+, % % " @ "$ " " % $ " ! " $ " ` " $ @ H% $ (( I '$ ! '$ 4 #. % @ " % " : 8 " 0 : ! " H0: I % "$ " @ ! " H3 I 0 " . % . " . " G "" % ( $ % % " % % " 0 ; % " A " < . ! % " % " % (( " ! . T < ! @ P " - % " : 0: "" % ( % " " 6% ! % " H3 I 0 & G " " % % " % " % % " % (( " ! % " " 5 (( " ! % . T % " $ " " * % @ H TI. % # % "

(40)

:7 ; ; <: 78 ; : 89 # % , " . "$ 484 9 H4 8 " " 4 @ " " ! I &. ( $ @ " " ! %" " . " " " * H3&I 0$ 5 " " " "$ " $ % 4 ( . "$ 4 : H4(( " 2 : I. % % # % " : 0: . % % " " % " " 5 (( " ! H33I " ( ! - " * 0 5 "$ %" ( ! $ $ % " % (( " H . T % " % (( " #I + % % " " %" " % " " " " " " " %" ` " % " " % " % @ $ % " % @ ! ' . " @ : / 1< " % @ " % (( " ! ! 4 1< H3 Q3-I $ "" G * 5 #T. "" ( " 5 T H3 I * . 5 % $ " $ 8: % 5 & 5 , " " '*. " H " I $ ( % 8: % 5 & H I 0 "

(41)

:7 ; ; <: 78 ; : 89 -C . " ! $ " % .3T % % 1 % 8: ( 5 &. 5 .#T % 8: % & 3. $ ( H . I , " " % " " % @ " " " %" %" ( % 8: % 5 & % %" ( % 8: % 5 3 H Q 3I 0 $ % "$ 8: 1 "5 P 5 3 T : %% " " % * ( G . "" " " "$ 8: , % $ G "$* ( "$ 8: * . $ " "$ 8: 8: " 5 .3 H( P I H I2 2 8: a & 2 " $ % % . % $ W 2 & f 8: a 2 = % . % W 2 f 8: a 2 P "$* . 5 % " Hg 5 % " " ( % I W 2 8: d 2 P "$* . 3 % " Hg % " " ( " I 4 % * 8: " d H( P .31 .3 1&.3I 2 2 8: a 2 % % . % W

(42)

:7 ; ; <: 78 ; : 89 2 f 8: a 2 = % % " % = " % 5 % " Hg 5 % " " ( % I W 2 8: d 2 % " " . % " . F " " . "$ 8: P 6" " " 9 "$ " "$ 8: % " P % . / " " % " "" " "= 8: " "" "" " " " 4 = . "$ G ( 8: ( 5 .3 *% @ P * . " = %" ! % H00 I. %% " 9B H% . % . 9 . BI 5 " H I % " " . " "= 8: % H I < 8: 6" P (( " "$ 00 9 "$ 8: % 1 .3. %" 00 . % 5 " " "= 8: < 8: P " 5 - %" . % " G % " % = % P (( " *% @ % ( . " % P " "= (( * 9 " % * P % . % % % % P ! " !. % " " " " " '*. %% " " %

(43)

:7 ; ; <: 78 ; : 89 "$* 8 " 9 H*89 I. 5 " " $ ( % H #I 0 " %" " . " ( " " " *+, % %% 5 " V ( . % ! ( *+, ( *+, " C 8 $ " $/ % $ % *+, " (" "$ " 0 % " " % " % " "" H -. I < % % ( ) 5 % $ (( " " 1 / " B 8 " " " 5 & % " " " @ *+, * H# I 9 " # . " " (( " ! % " % * *+, < % %" " P % $ 5 "$ " ( " B 8 " " ( . - @ H* ^ 3 *+,^ I H# I 0 "/ %" ( . !. "" D. 1 % " . " . % " " *+, * %" $ C " * 4 $ *+, . "$ " H " % I. ( " " $ % ( % $ H# I 9 " " " " "$ .

(44)

:7 ; ; <: 78 ; : 89 " " "$*+, H# I $ a S % @ 7F 70* % " " ! H "$ % ( . 7F " 5 70* " % " 5 *+, a S I $ . " " % P * "" . " *+, " " G " "$ !% D " " 4 . " % P " "$ (( @ @ H# I % " ! 00 % ( ( H 313 < SE I ( H ' . ' MI 5 " % " 5 3 < SE % " P " % 5 G % " H# I 0 " " % 5 " % % " @ . % " D " G C H#&I 4 ( . " ! M H D I ! " P " . % " . % @ $ . 5 " 3 H ! .3 5 3 $ "" % ( I H#3I " % $ " " D " % % " ! " '* % % 2 % " %" " ;*91B 4, H% % 2 "$ /% "" . " ( " . " ( % . $* 0. $ . 8: " " . C d 3 . " $ (" h . $ % $ " "I. " ;4 +:: ;*A49 H % " . $ " ". %" . C d#3 . % . . ;7* 6" . . . * 0I. " *7: * H $* 0.

(45)

:7 ; ; <: 78 ; : 89 C . . " @ . $ . /% "" I H# I 0 G $ " " " D % % V ( H##.#-I % 5 %" % : % ( ) . / 3 && % '*. 5 "$ " ;*91B 4, % %% ! ! %" $ " % % ( " H# I %% ". ;*91B 4, % " 5 % ( $ " H I 0 " " ; * 9 H;*9I. " ;4 +:: ;*A49 % % P % ( D " % @ C . " 1 % H I '$ ! '$ 0 " . " P "$ ! % * ( " . " (( " 2 "$ $ * 0 % $ % @ " " " % &T % " 5 T * H .- I 0 D " % '* " " % . 3T % 5 .& T * % % " 5 ( " H- I , " " % " " . " % " * . - T " " " /% $ @ H- I " " % $ " . " @ % . /% " . % 5 (( % . % % " " %" %

(46)

:7 ; ; <: 78 ; : 89 % G $ ! @ %% % @ "$ P " 9 " . 5 T % % " " % $ @ " . % " % " % H- .-&I < % " 3 "$ " $ @ " . . & % @ "$ P $ " " % . T. 3. T. #.&T . T H-3I 0 " " % " ! " !. " % G "" % % # H - 5 I % " (( " %" ( %% "@ " $ K (( L @ " . " 5 T % " . % " ! H" " $ %% @ % @ "$ $ % % " I H- I 4 & % " " "$*89 ! ! % 1 % " " "" " 08* 179 "$*89 0 ! % " * *+, "" H-#.--I 4"" " 5 % 9/ @ 8 " $ ( : "$* " H98 :* I $ % " " 9/ @ $ ( H 9 I $ " % " 08* 179 H8*0+:*1B:I % G ( % % " $ " " $ G " ! " ! " ! " $* H% i h( i

(47)

:7 ; ; <: 78 ; : 89 & " I "" "$ H--I $ # 3- % % $ ! @ D " % % *+, * " % G " % % (( " " % . " * . " % 5 ( " $*+, %" C H] - I " " %" 5 H "I ! " 5 ( $ " % "$*89 H8*0+:*1 V I . 5 "" . % G ( % . "" "$ "$ " . " $ G " % " H% $ * 5 *+,I ! * H-#I 0 / " & - % % % $ $ G D " % % $ * *+, H " $ " I % %% 5 "" * 0 % %" . " (( % % . $ 5 D % ( $ % " " " " '* % P " % " 0;* ,9 1 *9 % " 0;*,9 H- . I 0 ( " % * 0 % . ! % . % % (( . /% "" . d#3 . @ $* 0 $ H* 7I H ! % I %" . " 0;* ,9 1 *9 " 5 % "

(48)

:7 ; ; <: 78 ; : 89 3 " . C % 3 #& " ( . ! % 5 "$C d#3 9 " " . " 0;*,9 / %" $ " " $* 0 D " % / '* " " H " . *I " %" "" %" %"@ $* 0 D % . % " ( " . %% " " " 0;* ,9 1 *9 H " . *I 0 ! % $ " % * 0 D G '* 2 " " 0;* ,9 1 *9 D . " " " 5 H % * 0 "$ . TI. " " " % " 5 ! H . T % * 0. ( !% 5 5 3. TIH I 4 " $ % . 5 " P ( ( % % " % . 5 " " " H I $ ** % ( " " " " % ! " @ " 5 " (( . $ (( . % " " G $ " * % U " % ( " $ (( " " (( % " . " (" . ! % ( ) . ( % " $ "" H I 4 G &. " 0: /

(49)

:7 ; ; <: 78 ; : 89 % 5 "$ 0 7 " " " P "$ (( " * H I " . . . $ 1 "" " " % (" / . " / G5 " % . ! % / 5 "$ " " " 4 (( . " (" 5 " $ " @ % % " 1 "" 1 "" H &Q I * " $ G $ 5 /% % " / % 6 / H,:499 / I. % " ! c " . ! @ " H #Q I 0 (( " 1 "" "" " % H %% % " I. % "" " % P 5 "$ "" . % " " . ( , " (( " . % % . ! % "" " HV ( "I $ % "" ! " $ " 0 % %% " " V ( "$* ( . ( "$ G " ! " " / " 1 $ " %" " %" " H 3 5 &3 I % "" " "$ " " (( " @ % % % " " " H @ I H I 0 @ "" " "$* . ! 1 "" %" 6 D G G

(50)

:7 ; ; <: 78 ; : 89 # % ( " $ (( " . *+,. 5 " "$ G " % " " " " . $ " % 1N . " " " ! " . " ' G "" 3. % " % ! H I $ % ! *+, $ % 5 P " ( P " H . &I < " " % "$ "/ " % " "$+ 9 H+ " " 9 I " 5 ( " % " . 5 % . % G " % " % . H 3I % " @ " ! "$ % ! " ! " , % % " 5 " % ! " H . #I 0 % % 1 % 5 " " ,$ % . ! % % "$ " "$ *:1 H * : % I % A %" 5 " H #I < % "$ % 5 "$ ( "$ "$ " " " " *+, H -I , " % " (( " % ! " . % % "" . " / . ! %" " % P ( ( H I

(51)

< <B: 9

-<

"! %

"

$

$%

** " " "$ , ( " (( ! 5 G . " * % "$ % % " " % %" " H I 2 2 D " % % " / % " H'*. (" . / " I. 2 " " % " . 2 " " % $ % @ " " . 2 , %" " "$ % W 2 " " " " % 7 4 . " "$ % A" " . ! * % " $ % " " $ % " H 3I %% ( S ( " * " '* " 4 . " * %" " ( $* 0 "$ 3T H3 T % % -T % I " " " "$ 3T H I * % % (( " (( " % ! % . % " 5 "" %" H I

(52)

< <B: 9 " / % ! *+, ( " * (( % . " " . 5 " V ( H" ( " * I ! % 8 % 1 " % " *+, ! * %" % " @ 5 " V ( % % ! " "$ ! * 5 " % * 0 49 D " G % '*8 % " " 3 " 2 2 " 5 ( " H ! SGI ( 5 " V ( . " $ " % 5 ( H 3 ! SGI " $* 0 $49 H . TS . T. %a . I H I $ G ( ( " V ( H .# T . T W %a . 3I $ C " %" ( " V ( H5 ! SG 2 . T .#&T W %a . 5 3 ! SG 2 . T .#&T W %a . I 4 ( " $ % ( V ( H .3 T . TI W 2 " ! ( 5 " V ( " $* 0 $49 H . T .&T W %a . I H I ! $ G " " ! % 0 % " . " $ C %" ( " ! V ( H .3T .#T W %a . 3I " " $ % ! H . T . T W %a . I W 2 "$ % ! % 5 " V ( E $* 0 $49 H . #T . T W %a . 3I H &I ! $ G H . T

(53)

< <B: 9 & . T W %a . I " ! " H .3 . & W %a . 3I ( % ! V ( W 2 ( . "$ ! 5 ( " H SGI ( H SGI ( 5 " V ( " $* 0 $49 H 3I ! $ G H5 ( " . T .& T W %a . 5 ( .#3T .& T W %a . I " ! " %" ( " ! V ( " ! % G $ ! ( H .3 T . T W %^ . I

Tableau 5. Caractéristiques des essais cliniques des différents anticoagulants oraux directs dans la

prévention des AVC et des ES en cas de FANV.

% % % ; / :41 > H I :+0 47 *' H I *: 97+7 4 H &I 48A*A41 *' 7 &-H 3I "! : + 8 ( : , " 8 ( : , " 8 ( : , " 8 ( ; " $ - & & - 3 $ > ? . .- .-> ? # .3e-.# H /e,9I # H 31#-I H F 1 F I # H 1# I H F 1 F I # H &1#-I H F 1 F I 7 "$ >C? . . &.# . " <B ( . . .3 .

(54)

.-< <B: 9

&

0 ( & % 1 "/

(( " H:41 >. :+0 47 *'. *: 97+7 4. 48A*A4 *'1

7 &-I % & & % *+, # % % V (

H I 0 1 "/ " *+, @ ( " $* 0 $49 T % 5 " V ( H:: .- W 0 3T .# 1 . W &a . I % * 0 *+, " " " H . W .-31 . 3W &^ . I. " $ C H .&- W . 1 .3 W &a . I % 1 ! H . 3 W . 1 .33 W &^ . &I , " " " " . " *+, " %" % % . 5 "$ * . % $ " % " " " % % ! " " " (( % ( H % % " % V ( I " . $4 ( " " H #Q I *+, " 5 ( % ( H I 4 ( . "$ " *+, " % 90* ! " %" $ *7 *9 *09 17 3 " ! 5 " .3 !SG 3 !SG %" H &I 4"" " . " " " .

(55)

< <B: 9 & $ ( * 0 ( G $ % ! " 5 " % " 3 ! SG "$ * :* 941 "$ P % $ @ G . $ C . "$ ( $ @ H 3I

Tableau 6. Caractéristiques des essais cliniques des différents anticoagulants oraux directs dans la

prévention et le traitement des maladies veineuses thromboemboliques.

% % % ; / :410+ 4: H I 4 8974 81, 7 H IS 4 8974 81 4 H I * '> H -I ;+ <9* H #I "! : , " " 8 1 ( : + 8 1 ( : , " " 8 1 ( : , " " 8 1 ( 74 7 S 4 74 74 ; " $ 3 - && S &-3 3 - & . > ? 33 3-S 3 3# 3 $ $ > ? S S S S 3 ! SG 3 ! SG H GI % SG ! SG H#GI % 3 ! SG / ; " T 3-T T T &T j 74 2 " "

(56)

< <B: 9 & ! " " '$ - ! " . 6 " $ * $ D 0 < ( " % P 5 "$ " $ % * 2 $ (( " @ H0"0 a S S .# bI. " % * "" H I 4 $ % " % " * P % "" 8: H I * 1 "5 #3 . " ! " G C H I % "" . % P $ " . " % " $* %" ( " D " G C D " G G H #I. " " ! * "$C " % % " ( " % " "$C " " " H -I ! " ! #! ! ,$ "" " % " ( . " (" " % " % " $ U (

(57)

< <B: 9 && "$ (( "$ " . ( " " H I $ #% !% % "/ % % " P ( " $ % * , " . 0> 0 . "$ D/ % " " ( " " " ( . 5 " " " % "" ! " H . I @ % % % @ (( & "" " 5 "$ $ $ / . " 0> 0 j 0> 0 j / " % 5 T 3T % %% 0> 0 j "$ 5 T H I < % "/ % % P 5 "$ $ " $ (( * " @ % " % " " " 5 " % !/ 0 " % " @ +:0 H % ! %" ! I. % 5 "$ $ " " % ! * H I , ! % "/ % " ( % ( "$ (( 5 " @ 4 ;N H % "$ % !/ / " 1 % " 1 " % !/ I 0> &' H5 "$ "$k1 / !/" " I H &I * "$ " " "$ (( " (" (( % % "/ % " % +:0 " 0> 0 . 0> &' . "$4 ;N H 3I

(58)

< <B: 9 &3 % % % "/ % "$ $ * D % % & % " % H Q -I < K " L " H ( I 5 " V ( % " . " @ " $ "$ " 48A*A4 *'17 &- % "$ ! 5 " V ( " '*. P ! % "$ $ *+, H I & ! % % " " * % " " H " #I H & I "$ . "$ P $ ( "$ . " $ (( 6" "$ 8: 5 G % @ ( , /% % / " " * " 5 2 "" " " " " " . " % /"" . " " . " !. " ! B ! "" . " % . " % . " . " " ( " ( . " H & I " " " " . " " " . " . " " . " " " "$ (( * " % " " " " G . " . " H & . & I

(59)

< <B: 9 & ! " ! #! ! ,$ "" " % " ( . " (" " % " % " $ U ( "$ (( "$ " . ( " " H I

(60)

< <B: 9

&#

Tableau 7. Médicaments pouvant interagir avec les AVK.

$ / ** " $ H & I $ / ** " $ " " 1 '$ * % 5 ( H 1 (" 1%/ " <A,I * 89 %/ D " D " /" D "" % " " * % H %/ " <A, <A,I * 89 H ( %/ D " I '" 1 " 8 % 9 "( ! D " " " " $ / *"" % ". " *"% % " * . * @ * H ( " . ( % D . ( . ( ! . " / . / " . (" " . " . "( . ( % I 0 H]- SG I * ( D " 2 S(" S S D " , D " , "( /"% " ; % ;/% " % H ( I + " " ! (/"" " % ( : % " 7 ! (@ 7 " 7 " * " H% " V ( "$ "I * " D/ * % * ! H ( D. . % I *% % B 0 " / A ( " 9 "( " 3 " *" " H ! % I , ( % ! 7 "/ * %" * % 5 <A,j <A, 2 " @ "

(61)

< <B: 9 &-6 " $ * $ D : * "$ $ % *+,. " ( " % / P " 4 (( . % . " % -3T " ( " H -I $ !% % .# % D " % % (( " @ :*,*N*M 1 $ (( " @ . % G % " $ (( " H -I % $ (( " % ! ( %" 2 .&. .3 . % $ (( " " @ . @ . "$ " " ! T ( H I % " 5 % $ (( " @ H I "$ % ! . " %" % . &&T % D % $ (( " " @ . @ H #I 0 % 3T " $ % ! " % " % " "$ % ! " 5 % $ (( " @ ( " % " % " <, 1 " /" ( % " 1 G . "$ (( % $ (( % !% % % " P

(62)

< <B: 9 & 1 D " G % (( % ! "$ % ! . " % " ( 0> &3 . " 1 D " % % % 5 " % 5 H & I $C "$ !% & 5 T % %% ! G G . " % " P % D " G #3 %" H -I % C % ! % ! % %" $ 5 3 T % %% ! G G 9 % % " $ " ! ( "$C % . % P D " % % % ! % $ ( H #I $ '! ( )% ! "" " " $ T 5 T D " % " % ( 5 E * % $ % " " ! 5 "$ % ! R " % " P " % % ( 5 E $ " % $ ( H #I

(63)

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

(64)

< <B: 9 3 % % " I. " " H 5 % % I. " " " H & I " D/ " ( % % ! "" *+, $ " ! " % 0> *& " ( % . " % / h . " D % . " % ". " "" % . % U %" ! . % "" H & I , " P @ . "$ ! ! % D/ " "" . % P 5 "$ $ " " "$ % ! " P $ " ! H & I " " @ 5 " " !. "$ *+, 5 "$ /" " /" 1 ! 1 (" . " %/ $ " @ 1 ! H<A,I. "" ! " %/ <A,. ! $<A,. 5 % % ! <A, H & I * " 1 (" h . " *+, "" 1 " % /" D " " ! %" 5 % % 4"" "@ ( $ % $ %" " " h . " % % " " .

(65)

< <B: 9 3 " " ( " . "$ % " " ! 1 / " *" " * " $ %" 6 " H &- # % " V ( I. " *+, 5 "$ " $ % %" 7 ! "" $ 5 % "$ ! 5 5 & % "$ % ! H &#I 0 % " % % % $ $ (( % " % 1 ! " " (( 2 "" " V ( $ $ " "" *+, % % & "" " " " H &#I * . " $ " * % *+,. "$*+, P % @ P "$* . " "$ 8: % " " H " "$*+, %" I H I * "$ . " *+, % * . "$* G % *+, P " " % 8: " H ! % ! I % @ G $* H ! " I 0 $ '$ $ 0 % . " " % % * ( $ C "$ 8: ( $ " " $ " . " *+, " /% 0 % % " " . " $ % % % " %

(66)

< <B: 9 3 0 G ( % " " (( 5 H &-I 2 1 " "" % %% ! * . 1 % " "$ (( " " " . 1 ( P % " . 1 % $ . 1 1 % % % "$ (( " 5 "$ P . 1 " @ " % G " % " 0 * ( " 9B % *+, % %" %" ! 2 (( . " ! " ( $ % " 5 "$ 6% " % ( H* % % 3I " " ! M H D I. ( ' $ % " " % ( % " "" " 0 % " (( ( %" % " " (( " " " % " 1 H&3 I H & Q 3 I * "$ . " ! "$ % ! % % $ % ( 5 % " 0 % $ "$ ! "( H ( N ( I. % @ (( " 1N , !

(67)

< <B: 9 3& % % " " " ( "$ (( " " . @ " D " . " "$ % ! H*884N*1*I ! H*884N*1:I H 3 . 3 I $ (( "$ ! $ % " . 1 $ . % P % " " "$ % %" < % " " % % % ( % @ " " . % " G $5 5 % @ " ( " % ( < @ "" H*884N*1&I " ( "$ ! @ " D % % % 1! 4 ( . "$ % D H 4: ##. 0 % MI % % / @ . % " " % " " $ " *+,. " % % " " . " ( % ! H 3 . 3&I " % ( "$ (( " " . " 1 "5 & . 5 "$ ! . (( % " 0 ! " 1 " ,$ % . " % "$ *+, ( . % % 5 " % " 9 "$ %" "$ % * 0 49 D " % '*. ! ! !. " % ! $ G " % *+, ( % % ! $ G " % (" H " -I H 33Q 3 I % ! *+, ( % / " 2 " .# ( %" 9 $ 0 . " ' " ( % ! H I P ((

(68)

< <B: 9 33 % " * " " % - ( %" B " % ! ( ) $ "/ ` % % " " % % % " 5 %" @ " . "" 1 % % % " " $ " % ( " ` % < " " % ( " ! "/ ` S (( *+, 4 % H I * ". D % / % " 0 % " *+, ! * . " " *+, ! %% %" ` " *+, * H % % " % ! " ` . " ` / $ 8: " -. I " " " ` % F " /1* G ( > HF* >I H I % % " " "/ " *+, % " G %% ` S (( % " H ( 5 % F* >I ( "$ % $ % ! " 5 ( % " "" % %% ! *+,

(69)

< <B: 9

3

Tableau 8. Coût des traitements anticoagulants oraux en France.

H 3 I % H 3-I % H 3#I E * H 3 I 6 $ H 33I " " - % % % % , 3 3 3 0 ` H % I H I #&. & . # .3 3. - .# 0 ` G " H I .&# .&# . 3 . . : %% % ! " S % ! (" . . 3. . & 0% 2 % 0 $ 0 " 7 % % " ! M " N " M % "$4" M ( " % " " " "$ % * 0 49 D " G % '*8 H . . I 0 " 7 % " " 5 "$ $* " 9 " : % %% ! * H*9 : I % % " P " 9 " : H9 :I % 4 G 3. " *+, " " '* % " ;*9. " " 9 : 5 ( H9 : I 9 : % % " ! H -I $*9 : G % "$ % ! H*9 : I % %% ! * . " " " ! / " *9 : ;*9 %% " " " %"

(70)

< <B: 9

3#

*+, . ( $ 8: " " 1

$ " ! * ! M / !

5 T % " "

Tableau 9. SMR et ASMR des anticoagulants oraux.

"$ " " $ $ " " $ 0 M H &. 3I % 8* '" M H I % 8* 9 M H #I % 8* 1 M H -I % 8* " $ $% " F ! M H Q # I ! H I N " M H # Q #&I % 1 ! H I " '* " % " 7 S 4 1 H I % % 7; 7A 4" M H #3. # I % 1 H I " '* % % 7; 7A 1 ! H I " % " 7 S4 8* 2 %%" " . '* 2 ( "" " . 7 2 % ( . 4 2 " % " . 7; 2 % @ " . 7A 2 % @ " j0 % 2 V ( ! % . " "$ 0 $ " $ $% @ " " ! . % " . " % . 1 . @ % % " 0 ( G $ (

(71)

< <B: 9 3-"" " "$ " . % %" %" ! 5 % % 0 " %% " "$*89 K " % % ! " %% U %" %" "" * "$ "" " . " % L H ##I * % " ( % " % " (" . "$ " 5 & . " % " V ( H I " % "$ " 5 H " I 0 " %% (" ! " % % % " % " . " 6" "$ 8:. " $ @ , %" % % " " ( " "" " " * "$ . "" % % " $ % % " *+,. !1"5 % ( " " H ! " I % " H ! % ! I " % % % %" H " ! % I 0 "$ 5 %" % . *+, H ( I % $ " . % % " $ . $ @ (( % " (( % % " "$ " ( % * "$ * " " "" " " ( " "" % & % "

(72)

< <B: 9 3 * % " " % % " (( " 5 "/ " ! " "$ 8: % H 5 % " @ % " . "@ % " @ $ I. " " P ! " *+, " %" ( " %" ( H . % " . % "$ % $ % I 9 "$ % % % & % "$*89 . " % % " % % " 5 % % ( "$ % *+,. "$ ! $ %" H( &I H #-I 9 "$ %" ( . " $ % . %" "$ % " % " @ . " ( " % . % . % " 0 " . % % . " %" ! % % *+, 4 %" . " @ (( % *+,. " " (( $ P " "

(73)

< <B: 9

(74)

; :; 8 0

$

0 " % G ( ( " ! " " ! ' "$ *+,. $ %" % " @ ! H ( I " " 5 " % " " $ ! % % " . " $ % " % @ % " % "$ ( 5 "$ " " ! % % " % * 0 H . * 7I H " "" B +97:+ 4I 0 "/ "$ /% "" . "$C "$ /% " " " % % ! @ ! % " %" $ * D " G '* "" . "$ !% ! * " "$* 0 $ (" ) % "$ " % H " . . % " (I 5 4 % ""@" . $ $ 0 ; % " % % H0 % " B I H . &. I % "$ " % % " !. $ "$ % " " *+, $ %" % ( " ( 5 " $ @ D % % " ! 0 "$ % *+, " ( ) . " % " (

(75)

; :; 8 0 . " /% $ @ * . % ' . " ! @ % " $ ! % % % . " % % ( $ " . ( % " " *+, 0 " 2 " % @ " % @ " % 8 1 10 " % %" G ( U " $ ( " *+,. "" " " % % " " "" " H " " % I " %" *+, 151 * " % " 0 " ( " ( ! *+,. % P ( % " ( " $ %" < % % % ( "" 1N . P $ " ( " " . "$ . % % % ! " " " " % " ;*9 ! % " *+,. " 5 % % % $ (( H C 5 " % % % " ( " "" (( I 5 "$ 6% " H0 ; % " < H0;<I "" I 0 " " (( % % $*+, % " ! ( ) . % % "" S 6% " 4 . " % % $*+, . "" "$ . % $ $ "" 1 ( ! "$*89 . ! 1

(76)

0 89 <B <B

$%

"! "!

$ * " $ '$ / ! '$ ! '$ 3 / " $ $% * $ " = $ /$ " ! . $ 0<= / 0 1 0< * ! " ' + ' % ( " % "$ % % " % * 0 " . " '*. G 6" G " @ " . G ( . . "$ " $ " ! H &#I '* " % % " " / 5 @ " $* 0 1 " H # I 0 D % '*. " % "$ " 5 "$ $ . 5 / ( " " . 5 $ /% " " " / . % P 5 "$ $ " H " %" I 0 % . 5 "$ " % $ / " % . . l . " @ " $* 0 D " G '* 5 ( %" ( " % % " " H - I '* % " 3T * 0. "" G $5 3T D " %" # H - . - I

(77)

0 89 <B <B & B "$ (( * " % * 0 D " G '* % " " . " $ 5 G % %"@ 6" !%" " $* 0 " % % " ! " " @ . 5 "$ % $ % * H" *+, $ % " " " "$ I % % " % * 0 0 " $ " % G B +97:+ 4 H ; % " : 0" &. % % " : B I "$ G ( " @ % % % / % * 0. "$ (" % " HC . ( " . ! % / % " " . % "" . % 5 "$ mI. % " H ) % " % % " " 5 I " H / E % 1 (" . % $ . ( "$ mI " " " " " . " " " (( ( G ( % . ( " !% ! * . " % ( " % / % * 0. " " * 0 " " 5 , % ' 0 "/ 5 % $ 3 " ! P % . % "

(78)

0 89 <B <B 3 ( " % " @ % % % " H " % I % " H . " % " % %" " I 0 % % " " " % . % " @ 0 /% $ %" " !% . % ( " % . " ( ( . 5 "$ " " " " % " 1 " H - I 0 " B +97:+ 4 " ( " %"@ . " % % $ " " 6" "$* "$ %% "$* 0 H (( OI G ( ) % % G 3 " 7 " G " &- % @ " " * 0 " " B H , / I 0;< "" " " " " /% $* 0. * 0 . * 7 % % ! " . #@ G @ " "" @ % % % @ % " " % " % @ " % " "" " "$ " " " $ P "

(79)

0 89 <B <B " !%" . 5 2 " % % HC . I. "$ !% ! H* . %" I. " "$ H* 0 . * 7I . " ! % " " . "$ " % 5 % 1* 0 " " . " "$* 0 H 8 ;99 2 8 " ( ; " 9 E 9 I. " % H : E I. "$ ( % H 94 2 " 9 4! I 0;* ,9 1 *9 " " % % % '* 0 %" " 2 (( . /% "" . C d #3 C 3 #& . @ . $* 0 $* 7. % " " ( H # I ;*91B 4, " " " %" 6 2 % % ( " H % % % I. "$ /% "" . (( " . (( % . $* 0. . 8: " " . C % " 5 3 . " % $ 1 (" h $ % " $ " " H -&I * "" $ % % % % ! ( " H /% "" . $* 0. . C % " 5 3 . % $ 1 (" h $ % $ " "I

(80)

0 89 <B <B # % @ % " " % % " ( " % $* " % ( 5 " " . " " " % " (( ( " % " % % " % J " ! 1 J / " " " % C χ " ' " % % " " % $ '* D ! / % * 0 . ( $ " % % " $ "/ 4 ( " G % " " * 0 ( % " ( ! % % " . " H" &a . I (( " " " @" " + : H %% . +:I % " "" ( 5 3T H 0 3TI - ! ! * "$ " . " % % " % &## % % % " % % " "" " "

" &## % . # H#-TI % * 0 . - H &TI

(81)

0 89 <B <B -0 % "$ $ @ % % . "" , " % % " $ . & H#TI % ( $ % * " " * 0 2 - H- TI % (" H -TI % V ( H " I 0 % % % 5 " % " $ !% * ' % " % " (" H I " 8: % . H F 1 F 2 . 1 .&I H " . ( 3I % % " " " " 8: " "$ @ 2 T % / % * 0 * 7 % 8: ( 5 . " $ " 3 T 5 % 8: % 5 " % * 0 % " % ! !% ! * % %" ( " . %" C . %" /% . %" $ '* % ( " % % * H " I $C "$ /% "" ( $* 0 D " % % '* W " $ "" % % " 0;*,9 0;* ,9 1 *9 . ! % ! % C #3 %" . " " @ % % " % H . # I < % " ! ( " %" ( % % " "$ $ % * 0 " * 0. " % !% ! * % (

(82)

0 89 <B <B

$ " % 5 "$ . % %"

$ C . &

Tableau 10.: & & & +,(

0 > G 22? % $% :$ ; > G) ? > G )? < " '$ ! '$ * . . H F 1 F I # H3-1# I # H#&1- I H3#1#-I H5=5+

* . d#3 H a#3I. HTI # H I & H# I & H& I H5=5+

9 ! ( . HTI H& I # H3 I & H& I .

< $ / . HTI * 0 # H#-I H I & H# I H5=5+ * - H &I # H I H &I . * 0 H-I H #I H#I H5=5+ + # H 3I H I # H I H5=5+ + " H I H I 3 H I H5=5+ 7 "/ 3 H -I H &I H I . &

8 ;99 H&- I. a H d I & H3 I 3 H&&I - H3 I .&

% $% " . HTI '" - H- I J ( H -I * %" H 3I & H I 3 H #I H5=5+ 6 " $ '$ . HTI ;/% "" - H I - H- I # H I H5=5+ , @ H I H I - H -I . ;/% " " H& I H I H&3I . ' "" " - H #I H# I 3# H I H5=5+

7 S 4 & H#I & H I H#I .

* 0 & H I H -I & H I .#3

* 0 H I H I .

7 && H I 3 H 3I H I H5=5+

*" " # H 3I H I # H I .

-$ 3 ) = S8 HTI

" S& H#I S & H I -S& H#I . #

8 ;99. a H d I S 3 H- I S 3 H--I -S H- I .&3

: E . a H d I S& H# I S - H3#I #3S #- H# I .

-94. a & H d &I &3S H &I &S H I & S - H I .3 * 02 " ". 8 ;99 2 8 " ( ; " 9 E 9 . 7 2

(83)

0 89 <B <B

#

Tableau 11. Valeurs des INR en fonction de la nature de l'AVC.

>C? ;G )( 0< "! '$ -G(# 0< ! '$ G#

; = > I&1 I)? . H . 1 .&I .- H . 1 . I .- H . 1&. I

; H( H3 I H I

(J ; J) H -I H &I H3 I

)H ; J H I H #I

; K H I H&I H I

8: 2 " " D . * 0 2 " "

Figure 5. Valeurs des INR en fonction de la nature de l'AVC.

* ". - % '*. % 5 #T % !. H -TI % * ". & H3 TI % %" " H % % . # % %/ . I. H&TI % H* % ! " I D H -TI , % % . " H F 1 F I % 0;* ,9 1 *9 & H 1 I H " . * 0 S* 7 * 0 8:]& & a 8:f& # f 8:f & 3 8:a T T T T & T 3 T T # T - T T T

(84)

0 89 <B <B # ( I < % H TI 0;* ,9 1 *9 . H TI % 0;* ,9 1 *9 . #& H- TI % d * . . #& % . . '* ` P % * " " * 0. " 3 H &TI $ ! ( H . -3I " & % % * " . # H3 TI % %" 4 . +" (( " " % " 1 % % " ! H - I " " " @ % % % ( " %" " 2 " ( % ! $* 0 $* 7 %% " ( 5 T $ !% ! " ! " @ " " " 0;*,9 ! "" G $5 # T 8 $ % % % % "/ " " % G ( 1 ! * 5 "$ $ % " " 1% % H - I 8 % % % ;*91B 4, % 2 % " G " % * H ^& I. H 3TI % " H;*91B 4,d I % G ( $ " H (( % P 1 . " / " " ! % ( " I < " " % % " 0;* ,9 1 *9 " %" " % % *+,. G ( D % % ;*91B 4, " H -#I 0 % " " " 5 ! HC . /% "" . $* 0I , . "

(85)

0 89 <B <B # % '* % * % 0;* ,9 1 *9 % % %" + " " % 5 ! % % " " %" ( " % @ * H @ $ % % I H I % % " % " % ' 5 "$ . . " ( D " % % " " G H --I G ( % % " % % "" 1 H G ( I. $ . %" . " "$ @ H --I + % G $ " '* % " $ 3T * 0 "" G $5 3T D " % # %" H - . - I * 0 D " % '* " %" @ ! / $ " ! " %" " . ( %" @ . G ( " H - I V ( " $* 0 -T D " % '* H I , % % " G '*. # H- TI % * 0 . D * . D H &TI * 7. ! * . H3TI C H " C D " G % * I * 0 ! " = " D " % % * H " I

(86)

0 89 <B <B # Tableau 12. -, . /(, 0 & 1 0 . HTI > G,)? % $% :$ ; > G(#? > G+2? H I H I H I . - H I H&I # H I .& d #& H- I 3 H I & H- I .

Figure 6. Scores CHA2DS2-VASc chez les patients en fibrillation atriale.

0 %" % " % '* / % * 0 . !1 % " P " "$ "/ (( "$ " " % % " 2 " % % * %" C . %" /% . % %" /% " " ! % * % % * %" ( ! % * . G ( " * ( " G / % * 0 % * H ^ I. " $ % % " $ (( "/ D % 1"5 * + * 8 0;* ,9 1 *9 d -0;* ,9 1 *9 ^ & 0;* ,9 1 *9 ^ T T T T & T 3 T T # T - T T T

(87)

0 89 <B <B #& 8 % "$ !% ! * ( % "$ " H I % ( " $ " % 5 " . % % 1* 0. % . % (( ( " % !% ! * "$ @ " % H " I " % " % @ " % '* / % * 0 H " I 0 ( 5 " % $ " 5 "$ " % 1* 0 < : 0 : * 0 " &- % '* / % * 0 "$ !% ! * "$* 0 5 "$ 5 " "$* 0. 5 "$ " " " "$* 0 H I , " % " : ? % ' E E % % V ( . "$ "$ " " "$ @ H* 0 $ " I 5 "" " % % 1* 0 H I 9 " " . "$ ( 5 " % $* "/ % $ !%" % % 1 % "$ % " . G ` ! ( " (( ( . "/ " " ! $ 8:

(88)

0 89 <B <B #3 : & & 1 & 1 0 > G#2? % $% :$ ; > G&#? > G+&? < " '$ ! '$ * H I. H F 1 F I #- H# 1-&I - H#31-#I # H# 1- I 5=5)

* . d#3 H a#3I. HTI H3-I H- I H3 I 5=5)

9 ! ( . HTI & H &I H I H 3I .-#

< " '$ / 0< + H I H&I . + " 3# H-3I H- I && H- I . 7 "/ # H& I H I H3 I H5=5+ 8 ;99 H&- I. a H d I H I 3 H I H I . $ " . HTI * %" & H I H I H# I H5=5+ * % H# I H I H3 I 7 %/ H &I H I 6 " $ '$ . HTI ;/% "" 3 H#3I 3 H &I 3 H I 5=5 , @ H I - H3 I H &I . ;/% " " 3 H3 I H#3I H&3I 5=5 ' "" " - H #I H I 3 H I .3 7 S 4 H I H I & H-I . * 0 H &I H I H 3I .#& * 0

7 3 H#I H I & H-I .

*" " # H I H I # H I .

-$ 3 ) = S8 HTI

" 3S H-I S 3 H I 3S&3 H I .

8 ;99. a H d I S& H# I S H##I S H# I .#

: E " . a H d I S33 H33I S 3 H& I &S& H I .

94. a & H d &I S H 3I S H I S H I .

* 02 " ". 8 ;99 2 8 " ( ; " 9 E 9 . 7 2 % ( . 4 2 " % " . 94 2 " !

(89)

0 89 <B <B # "" . $ "/ D " % !% ! * $ " % " 5 % %% 5 ! !% ! * $ / % ( "/ H ( I " . " % @ 1 . % @ G " "$* 0. " "/ (( D " % % * $ % 5 " (( % 1* 0 H I ! "# $ % # $ * 0 H * 0 I . . ( 5 8:] H I "/ " H " &I 9 " $ " "$ (( % " * . " ( 5 "$ @ " " " 1 ! . " " ( " , % 3 # H C % I 5 3&-. % $ $ @ H &I $ $ % "" " " " "$ , " P @ . 9 % $ $ C 5 % $ "/ % ! - % H *: 0. ^ 3# W 0;9. ^3---I / ( 3 @ H 3I * "$ " 874:97:+ 4. % * 0. * 0 . 5 . ( " " ( " $ C H+:. . 3 W 0 3T. . #1 . I H I

(90)

0 89 <B <B ## Tableau 14. @ + 9 3 ,( A,%8 0 . HTI ; $ / . $ . $ B " L 0< "! '$ -G# G(, : >4+C < ? : >4+C < ?

* H I. d#3 H a#3I H3 I H#3I . H . 31 . I . & 1 1

' "" " & H #I H# I . H . -1 .#I .3& 1 1 ;/% "" & H #I & H- I . H . 31 .3I . - 1 1 * * 0S* 7 H #I H I . H . 1 #I .#

7 H3 I H#I H .31 I 5=5( & H .31 - I 5=5(

8:. f H ] I H3 I 3 H I . & H . 1 .3I 5=5& . H . 1 .&I 5=5&

* 0 2 " ". * 7 2 . 8: 2 " " D 0 % @ " %" 6 $ % " % * " "$ " $ * 0 . $ % "$ (( % " " "$* " ( % " % % 5 % * 0 " "$ " . ! ' / $ " " = $ 3 0 * 1 $ % > " M&? B ?. A 9. /E * . , 1 "" 8. 0 0. , %" ,. / ,. B : (" ( % 1 E * !% % " E • < $ " ** "! $ " : = @ (5& B ?. A 9. : '. / ,. 0 0. B :. 0 ? 0 ( % !% " 1 " E % "1

(91)

0 89 <B <B #-$ " /$ " $ " $ $% N $ $ + * ! " ' + ' * "$ *+, " "$ '* H* I. " . " "$ " " . "$ K L % " * . " % " *+, 0$ ! %" "" $ ! % % " ! $ $ 6% " % % H0 ; % " B I " " (. "$ % $ ( 5 " @ 0 ; % " B . " % 1 Q0 " . B . " " " %" . " &@ " ; % " B % " $ (( / & % 0 " % H 5 I " " ! " . % *+, " ' . % % "$ % 474 % Q % 7; 7A $ % (( "" * "$ " . 5 . " G % % 5 " % * 0 49 D " G '*8 P " " & . " %

(92)

0 89 <B <B # 0 % % "$ " " % % *+, ( % % % % . "$ " % ( " % ( " . " $ ( % "" ( 5 " $ " * H "$ % . " *+,I , ' % 5 % " . % % "" % ! $ $ % " $ 2 K % $ L % $ ( /% $ @ " !. " $ " " "$ (( , %" "" % "$ P $ " % 5 " % " %" " . % %" " " " $ % $ ( " @ " %" ! % " " % % " ! , ". "/ % (( " (( % "$ H " " . " % I. 1 . 5 " ( $ @ * . " " % @ % " " ( " % 5 % ( H% "$ @ ! 5 "$ % " . ! " I. " ! % % . % " @ ( . ( !

(93)

0 89 <B <B -P % % "" " % " $ ( % " % 5 H I "$ !% 0 % " $ " % . 5 ( 4"" % " $ %" ( $ @ 5 " ( & # $ " " $ $ "" . . 0 ; % " B % 5 5 . G 5 & G 5 % " " % " $ 0 ; % " B % " ! "" "$ " % . " % ( C 5 P " $ $ 8: (( % " " $ " "$ % ! " % & . " % ( C 5 " %% " " " $ 5 ( @ $ " % . "$ ( @ C 5 " % % " " . " " H* *+,. % ! " " " % % " " I

Figure

Figure 1. Structure chimique des différentes formes de vitamine K.(14)
Figure 2. Cycle de la vitamine K. (14)
Tableau 2. Anti vitamines K commercialisés en France.
Tableau 4.Concentrations plasmatiques des AOD administrés aux doses maximales journalières
+7

Références

Documents relatifs

Using the Fo¨rster formulation of FRET and combining the PM3 calculations of the dipole moments of the aromatic portions of the chromophores, docking process via BiGGER software,

Later in the clinical course, measurement of newly established indicators of erythropoiesis disclosed in 2 patients with persistent anemia inappropriately low

Households’ livelihood and adaptive capacity in peri- urban interfaces : A case study on the city of Khon Kaen, Thailand.. Architecture,

3 Assez logiquement, cette double caractéristique se retrouve également chez la plupart des hommes peuplant la maison d’arrêt étudiée. 111-113) qu’est la surreprésentation

Et si, d’un côté, nous avons chez Carrier des contes plus construits, plus « littéraires », tendant vers la nouvelle (le titre le dit : jolis deuils. L’auteur fait d’une

la RCP n’est pas forcément utilisée comme elle devrait l’être, c'est-à-dire un lieu de coordination et de concertation mais elle peut être utilisée par certains comme un lieu

The change of sound attenuation at the separation line between the two zones, to- gether with the sound attenuation slopes, are equally well predicted by the room-acoustic diffusion

Si certains travaux ont abordé le sujet des dermatoses à l’officine sur un plan théorique, aucun n’a concerné, à notre connaissance, les demandes d’avis